BRISTOL-MYERS SQUIBB $47.40

up +0.40


24/5/2013 04:24 PM  |  NYSE : BMY  |  Industries : Manufacturing / Pharmaceutical and Medicine Manufacturing
12 Mo. Price Change : 45% - BMY has outperformed the S&P 500 by 20%

Get Trend Analysis Icon Get Trend Analysis

Partner Headlines

  1. Odd, This: Big Pharma On Losing End of Pricing Dispute

    YCharts

  2. Bristol-Myers in $480 mil pact

    Investors Business Daily

  3. Judge to Bristol-Myers: Patent on $1.4 Billion Hepatitis-B ...

    YCharts

  4. UPDATE: Jefferies Raises PT to $41 on Bristol-Myers Squibb on ...

    Benzinga

  5. Bristol-Myers Inks $438M OTC Drug Deal

    FOXBusiness

  6. A Peek Into The Market Before The Trading Starts

    Benzinga

  7. Bristol-Myers Squibb Enters 3-Year Agreement with Reckitt ...

    Benzinga

  8. The Medicines Co., Bristol-Myers Begin Alliance for Recothrom

    Benzinga

  9. Pharma's Pay-to-Delay Deals Face Further Opposition: Senate Bill ...

    YCharts

  10. Pay-to-Delay Opponent, FTC Chief Leibowitz, Quits: Respite for Pharma?

    YCharts

  11. Novo Nordisk Earnings Beat Views; Competition Looms

    Investors Business Daily

  12. Are We Saps? Getting In On Pfizer's YTD 7% Gain, But Missing the ...

    YCharts

  13. Pfizer Stock Hits High On Earnings, Talk Of Split

    Investors Business Daily

  14. Pfizer, Lilly Q4 Results Shadowed By Drug Launches

    Investors Business Daily

  15. Celgene, ResMed, Bristol, Biogen Stocks Move On News

    Investors Business Daily

  16. Medical Stock Wrap: Celgene, Bristol, Baxter, Biogen

    Investors Business Daily

  17. Bristol-Myers Beats the Street in 4Q

    FOXBusiness

  18. Futures A Wide Mix On Earnings; Apple Crumbles, Netflix Streams

    Investors Business Daily

  19. US Stock Futures Mixed After Disappointing Apple Results

    Benzinga

  20. Earnings Scheduled For January 24, 2013

    Benzinga

  21. Earnings Expectations for the Week of January 21

    Benzinga

  22. Week Ahead: Apple Earnings, Housing Data

    FOXBusiness

  23. AbbVie, Abbott Spinoff, Starts Life Near Top of Pharma Industry's ...

    YCharts

  24. FTC: Pay-to-Delay Pharma Deals Cover $8.3 Billion in Revenue

    YCharts

  25. Bristol-Myers' $1 Billion Drug at Center of Debate Over HIV ...

    YCharts

  26. Bristol-Myers $2.5B Inhibitex Deal a Disaster – For Patients and ...

    YCharts

  27. UPDATE: Jefferies & Company Reiterates Buy Rating, Raises PT on ...

    Benzinga

  28. Santarus Wins Drug Approval, Offers Bullish Guidance

    Investors Business Daily

  29. Medtech Stocks Moving As Conference Makes Waves

    Investors Business Daily

  30. Medtech Stocks Moving As Conference Makes Waves

    Investors Business Daily

  31. A Peek Into The Market Before The Trading Starts

    Benzinga

  32. Tranzyme Completes Drug Discovery Collaboration With Bristol-Myers ...

    Benzinga

  33. Good News For Pharma Stocks: FDA Drug Approval Speedier

    YCharts

  34. Bristol-Myers, Pfizer drug OK'd

    Investors Business Daily

  35. Bristol-Myers, Pfizer Stocks Rise On Eliquis Approval

    Investors Business Daily

  36. Benzinga's Top Upgrades

    Benzinga

  37. Benzinga's Top Upgrades

    Benzinga

  38. Pfizer

    Investors Business Daily

  39. Patent Victory Gives AstraZeneca Time to Develop New Drugs: Bad News?

    YCharts

  40. You Can Expect More Insider Trading in Pharma Stocks: Here's Why

    YCharts

  41. Abbott Laboratories (ABT) Dividend Stock Analysis

    GuruFocus

  42. Stocks to Buy on Dips: Teva

    GuruFocus

  43. ELIQUIS Receives Approval In Japan for Prevention of Stroke, ...

    Benzinga

  44. Abbott Laboratories: Quality Dividend Aristocrat for Long Term ...

    GuruFocus

  45. UPDATE: Goldman Sachs Reiterates Buy Rating, Lowers PT on ...

    Benzinga

  46. Bristol-Myers Squibb Company (BMY) EVP & CFO Charles A Bancroft ...

    GuruFocus

  47. Why Some Companies Are Not Accelerating Dividends

    FOXBusiness

  48. This Dividend Stock Traces Its Origin Back to Oldsmobile

    GuruFocus

  49. Bristol-Myers, Abbott Announce Results from Phase 2 Multiple ...

    Benzinga

  50. Bristol-Myers, Pfizer Announce Positive Phase 3 Trial Results for ...

    Benzinga

  51. Citigroup Reiterates Neutral Rating, $33 PT on Bristol Myers Squibb

    Benzinga

  52. Alzheimer Failures Elsewhere Don't Deter Merck: Phase II/III Study ...

    YCharts

  53. Pfizer, Stock Rising on Cost Cuts, Plans More Staff Layoffs

    YCharts

  54. Accenture Life Sciences Study: Worst of Pharma's Patent Cliff is ...

    YCharts

  55. Name an Industry That Can Jack Prices Up 13% in This Economy

    YCharts

  56. Gilead Hep C Drug Meets Expectations In Phase 3 Trial

    Investors Business Daily

  57. Becton, Dickinson and Co. (BDX) Dividend Stock Analysis

    GuruFocus

  58. Abraxane Cancer Trials Help Justify Celgene Buyout

    Investors Business Daily

  59. Johnson & Johnson (JNJ) Dividend Stock Analysis

    GuruFocus

  60. Bristol-Myers Squibb's Investigational Hepatitis C Compounds ...

    Benzinga

  61. Short Interest Swings in Biotech Stocks (AMGN, BIIB, VRTX)

    Benzinga

  62. UPDATE: BMO Capital Markets Downgrades Bristol-Myers Squibb to ...

    Benzinga

  63. New Head-to-Head Patient Reported Outcomes Data for Orencia

    Benzinga

  64. A Peek Into The Market Before The Trading Starts

    Benzinga

  65. Big Pharma on the Defensive: Sanofi Caves on Oncology-Drug, ...

    YCharts

  66. Take an Out-of-Work Drug Rep to Lunch: More Big Pharma Layoffs

    YCharts

  67. Irving Kahn's Top Sells for the Third Quarter: SYMSQ, CVX, ATT

    GuruFocus

  68. Moves in Smaller Health Care Stocks (GMED, SEM, UAM, VRTX)

    Benzinga

  69. Merck's Mighty Januvia: The Diabetic Investor Explains a Huge, ...

    YCharts

  70. Valeant Earnings, Guidance Beat Street's Estimates

    Investors Business Daily

  71. Bristol-Myers Squibb Receives Positive Decision from NIH for YERVOY

    Benzinga

  72. Novo Nordisk Beats Estimates As FDA Decision Looms

    Investors Business Daily

  73. Pharma Merck Earnings Beat Estimates, Revenue Misses

    Investors Business Daily

  74. Eli Lilly misses on generics

    Investors Business Daily

  75. BristolMyers Squibb Company Reports Operating Results (10-Q)

    GuruFocus

  76. Bristol-Myers, Eli Lilly Miss On Generic Competition

    Investors Business Daily

  77. Bristol-Myers Sales Slump 30% on Generic Pressure

    FOXBusiness

  78. Earnings Scheduled For October 24, 2012

    Benzinga

  79. Gilead Profit, Sales Beat Estimates As HIV Drugs Boom

    Investors Business Daily

  80. Global Squeeze on Pharma Prices Just Won't Ease Up: Canadians Iffy ...

    YCharts

  81. Week Ahead: FOMC Meeting and Earnings

    FOXBusiness

  82. Ah, Geez, the Aussies, Too? Plush Patent Rights of Big Pharma ...

    YCharts

  83. Pharmaceutical Stocks Are All-of-a-Sudden Hot Again: Read About ...

    YCharts

  84. Pharma Industry Agrees to Price Cuts With Irish Government: More ...

    YCharts

  85. Abbott Labs Beats Earnings Views; HCV Trial Launched

    Investors Business Daily

  86. Golly, Big Pharma, This Emerging Markets Strategy Isn't Looking So ...

    YCharts

  87. Good marks for hep-C drugs

    Investors Business Daily

  88. Abbott, Bristol-Myers Pop On Hepatitis C Drug News

    Investors Business Daily

  89. Lilly Stock Up On Good News For Stomach-Cancer Drug

    Investors Business Daily

  90. Celgene Drug Abraxane OK'd For Lung Cancer; Shares Up

    Investors Business Daily

  91. Pharma's March Into Emerging Markets Hits Yet Another Rough Spot

    YCharts

  92. Bristol-Myers Squibb Says Orencia Approved by EU

    Benzinga

  93. Tom Marsico Favors Health Care Names Like Biogen Idec

    Investors Business Daily

  94. Celgene Melanoma Drug Test Positive; Stock Rises

    Investors Business Daily

  95. ELIQUIS Reduces Stroke and Systemic Embolism Compared to Warfarin ...

    Benzinga

  96. Bad News For Pharma In World's Second-Biggest Market

    YCharts

  97. Lilly Looms Over Patent Precipice

    GuruFocus

  98. Bristol-Myers Presents 4 and 5-Year Survival Data for YERVOY in ...

    Benzinga

  99. FDA Acknowledges Receipt of Resubmission of the ELIQUIS

    Benzinga

  100. A Big Part of the Pharma Pipeline is Struggling: Biotech Startups

    YCharts
People viewing BMY also viewed: , , , , , ,
Marketplace
Trading Center